Canada is the only country in the world with a national healthcare plan that does not include drug coverage. Coverage of necessary medications is a patchwork of inconsistent programs that does not always serve the very individuals it was created to help—those patients who need prescribed medicines. Our system needs radical, intuitive changes.
World Health Organization. Adherence to Long-term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
3.
LichtenbergFR. Do (more and better) drugs keep people out of hospitals?Am Econ Rev. 1996;86(2):384–388.
4.
LichtenbergFR. Benefits and Costs of Newer Drugs: An Update. NBER Working Paper No. 8996. 2002.
5.
SkinnerBJGrayJRAttaraGP. Increased health costs from mandated therapeutic substitution of proton pump inhibitors in British Columbia. Aliment Pharmacol Ther. 2008;29(8):882–891.
6.
HunfeldNGMathotRATouwDJ. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008;65(5):752–760.
7.
AlemayehuBKeXYoussefNNCrawleyJALevineDS. Esomeprazole formulary exclusion: impact on total healthcare services use and costs. Postgrad Med. 2012;124(3):149–163.
8.
WestJCRaeDSMojtabaiR. Clinically unintended medication switches and inability to prescribe preferred medications under Medicare Part D. J Psychopharmacol. 2012;26(6):784–793.
9.
WuEQYuAPLauzonV. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother. 2011;45(4):441–451.
10.
NguyenEWeedaERSobierajDMBookhartBKPiechCTColemanCI. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin. 2016;32(7):1281–1290.
11.
AndradeSEGurwitzJHCernieuxJFishLS. Evaluation of a formulary switch from conjugated to esterified estrogens in a managed care setting. Medical Care. 2000;38(9):970–975.
12.
CoteBRPetersenEA. Impact of therapeutic switching in long-term care. Am J Manag Care. 2008;14(11 suppl): SP23–SP28.
13.
ClayDRBourgMPLawrenceDB. Outcomes of an amlodipine-to-felodipine therapeutic interchange program. Am J Health Syst Pharm. 2000;57(17):1604–1607.
14.
JohnstonAStafylasPStergiouGS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol. 2010;70(3):320–334.
15.
RubinDTSkupMJohnsonSJChaoJGibofskyA. Tu1305 analysis of outcomes after non-medical switching of anti-tumor necrosis factor agents. Gastroenterology. 2015;148(4):S–853.
16.
LebwohlMSkupMYangH. FRI0123 clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons. Ann Rheum Dis. 2015;74(suppl 2):465.
